<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00027599</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02427</org_study_id>
    <secondary_id>UCSF-0155-01</secondary_id>
    <secondary_id>NCI-2617</secondary_id>
    <secondary_id>UCSF-01554</secondary_id>
    <secondary_id>CDR0000069047</secondary_id>
    <nct_id>NCT00027599</nct_id>
  </id_info>
  <brief_title>APC8015 and Bevacizumab in Treating Patients With Prostate Cancer</brief_title>
  <official_title>A Phase II Study Of Prostatic Acid Phosphatase-Pulsed Dendritic Cells (Provenge) In Combination With Bevacizumab In Patients With Serologic Progression Of Prostate Cancer After Definitive Local Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of APC8015 combined with bevacizumab in treating&#xD;
      patients who have undergone radiation therapy and/or surgery and who have progressive&#xD;
      prostate cancer. Biological therapies such as APC8015 use different ways to stimulate the&#xD;
      immune system and stop cancer cells from growing. Monoclonal antibodies such as bevacizumab&#xD;
      can locate tumor cells and kill them without harming normal cells. Combining monoclonal&#xD;
      antibody therapy with biological therapy may kill more cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the efficacy of APC8015 (Provenge) and bevacizumab, in terms of decline in&#xD;
      prostate-specific antigen (PSA) value and effect on PSA doubling time, in patients with&#xD;
      progressive prostate cancer.&#xD;
&#xD;
      II. Determine any immune response in patients treated with this regimen. III. Determine the&#xD;
      safety of this regimen in these patients.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Autologous dendritic cells (DCs) are harvested and pulsed with prostatic acid&#xD;
      phosphatase-sargramostim fusion protein to produce APC8015 (Provenge). Patients receive&#xD;
      APC8015 IV over 30 minutes and bevacizumab IV over 30-60 minutes on day 1. Treatment repeats&#xD;
      every 14 days for 3 courses. Patients continue to receive bevacizumab alone every 14 days in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous dendritic cells (DCs) are harvested and pulsed with prostatic acid phosphatase-sargramostim fusion protein to produce APC8015 (Provenge). Patients receive APC8015 IV over 30 minutes and bevacizumab IV over 30-60 minutes on day 1. Treatment repeats every 14 days for 3 courses. Patients continue to receive bevacizumab alone every 14 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>prostatic acid phosphatase-sargramostim fusion protein</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sipuleucel-T</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous dendritic cells</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>in vitro-treated peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Any T, any N, M0&#xD;
&#xD;
          -  Received prior therapy comprising one of the following regimens for primary prostate&#xD;
             cancer:&#xD;
&#xD;
               -  External beam radiotherapy&#xD;
&#xD;
               -  Brachytherapy with or without pelvic external beam radiotherapy&#xD;
&#xD;
               -  Cryosurgery&#xD;
&#xD;
               -  Radical prostatectomy with or without adjuvant or salvage radiotherapy&#xD;
&#xD;
                    -  Adjuvant or salvage radiotherapy after radical prostatectomy is allowed&#xD;
                       provided the following criteria is met:&#xD;
&#xD;
                         -  PSA was never greater than 6.0 ng/mL&#xD;
&#xD;
                         -  At least 3 months since androgen deprivation&#xD;
&#xD;
          -  Elevated PSA (0.4-6.0 ng/mL) that has increased on 2 measurements taken at least 2&#xD;
             weeks apart&#xD;
&#xD;
          -  No history of or radiological evidence of current CNS disease (e.g., primary brain&#xD;
             tumor, seizures not controlled with standard medical therapy, or brain metastases)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 2,500/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  No prior bleeding disorder&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST no greater than 2 times ULN&#xD;
&#xD;
          -  Hepatitis B and C negative&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2 times ULN&#xD;
&#xD;
          -  BUN no greater than 2 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No clinically significant cardiovascular disease&#xD;
&#xD;
          -  No New York Heart Association grade II-IV heart disease (symptomatic congestive heart&#xD;
             failure)&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No serious cardiac arrhythmia requiring medication&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No prior myocardial infarction&#xD;
&#xD;
          -  No grade II or greater peripheral vascular disease within the past year&#xD;
&#xD;
          -  No prior deep vein thrombosis&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV and HTLV I and II negative&#xD;
&#xD;
          -  No other uncontrolled illness, underlying medical condition, psychiatric illness, or&#xD;
             social situation that would preclude study participation&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No active autoimmune disease requiring treatment&#xD;
&#xD;
          -  No significant traumatic injury within the past 4 weeks&#xD;
&#xD;
          -  No serious nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No other &quot;currently active&quot; malignancy except nonmelanoma skin cancer&#xD;
&#xD;
               -  Not &quot;currently active&quot; if considered by physician as having less than 30% risk of&#xD;
                  relapse after completion of therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior immunotherapy&#xD;
&#xD;
          -  No prior anti-vascular endothelial growth factor therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No prior hormonal therapy (e.g., luteinizing hormone-releasing hormone [LHRH] agonists&#xD;
             or antagonists, antiandrogens, estrogens, megestrol, or PC-SPES) for progressive&#xD;
             disease&#xD;
&#xD;
          -  Prior hormonal therapy in adjuvant or neoadjuvant setting as primary therapy allowed&#xD;
             if at least 3 months since androgen deprivation&#xD;
&#xD;
          -  No concurrent systemic steroid therapy (inhaled or topical steroids allowed)&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery, including open biopsy or needle biopsy of&#xD;
             liver&#xD;
&#xD;
          -  No concurrent major surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 10 days since prior aspirin&#xD;
&#xD;
          -  At least 10 days since prior oral or parenteral anticoagulants except to maintain&#xD;
             patency of pre-existing permanent indwelling IV catheters&#xD;
&#xD;
          -  No concurrent aspirin&#xD;
&#xD;
          -  No concurrent oral or parenteral anticoagulants except to maintain patency of&#xD;
             pre-existing permanent indwelling IV catheters&#xD;
&#xD;
          -  No other concurrent experimental or commercial agents or therapies for prostate cancer&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric J. Small, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2003</verification_date>
  <study_first_submitted>December 7, 2001</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

